Home Market News Small Caps Why Is Alpine Immune Sciences Stock Trading Higher Today?

Why Is Alpine Immune Sciences Stock Trading Higher Today?

0
Why Is Alpine Immune Sciences Stock Trading Higher Today?

Alpine Immune Sciences Inc (NASDAQ: ALPN) recently presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology (ASN) Kidney Week.

In IgAN, treatment with low-dose povetacicept, 80 mg SC every four weeks, showed significant improvements in proteinuria, with a 53.5% reduction from baseline in UPCR (n=5) at 24 weeks.

Furthermore, at 24 weeks, 4 out of 5 (80%) patients achieved remission, defined as UPCR < 0.5 g/g and ≥50% reduction in UPCR from baseline with stable renal function (≤ 25% reduction in eGFR from baseline).

In IgAN, treatment with low-dose povetacicept was also associated with a >60% reduction in the disease-related biomarker galactose-deficient IgA1 (Gd-IgA1), as well as stable renal function as assessed by estimated glomerular filtration rate (eGFR) (+7.1% from baseline at 24 weeks; n=5).

The first participant with primary membranous nephropathy (pMN), also treated with povetacicept 80 mg SC every four weeks, achieved an immunological remission, defined as a reduction in the highly disease-relevant biomarker anti-PLA2R1 to an undetectable level, from a baseline of 209 to < 2 RU/mL by 22 weeks.

Povetacicept has been well tolerated, with no reported administration-associated reactions, no instances of IgG < 3 g/L, and no severe infections.

A higher dose of povetacicept, 240 mg SC every four weeks, continues to enroll participants, with initial data expected in the first half of 2024.

Alpine Immune Sciences’ stock (ALPN) is currently up 39.35% at $14.66.

Read Next: SolarWinds Shares Jump Following Q3 Results and Optimistic Full-Year Forecasts